We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PACLITAXEL PATENT CASE MOVES TO DAMAGE PHASE IN MAY
PACLITAXEL PATENT CASE MOVES TO DAMAGE PHASE IN MAY
January 2, 2004
NaPro BioTherapeutics did not obtain its formulation patents for a generic version of paclitaxel through inequitable conduct and fraud, a federal court ruled late December.